Five things for pharma marketers to know: Tuesday, March 1, 2016



1. Even after Addyi received FDA approval, the effectiveness of the drug is still being questioned.  An analysis found that the benefits of the hypoactive sexual desire disorder drug are marginal. The team analyzed data from eight trials—five published and three unpublished—of nearly 6,000 women. Valeant acquired Sprout, the manufacturer of Addyi in August. (Reuters)

2. Horizon Pharma disclosed that it received a subpoena last November from New York's attorney general regarding its patient assistance programs, according to a SEC filing. Valent received a subpoena about its PAPs in October.

See also: Pricing debate changes perception of patient assistance programs

3. AstraZeneca sold the rights to opioid-induced constipation treatment Moventig to Kyowa Hakko Kirin. AZ and Daiichi Sankyo ran an unbranded ad for opioid-induced constipation in the Super Bowl. The two drugmakers are commercial partners for OIC treatment Movantik, the US trade name of Moventig. (Reuters)

4. GlaxoSmithKline is searching for a new CEO next year to replace Andrew Witty. The shake-up comes as many of the drugmaker's largest investors are calling for the firm to split up, arguing that the company's HIV, consumer healthcare, and core medicine divisions should act as standalone business units. (The Sunday Times)

5. Roche received FDA approval in a second indication for its leukemia drug Gazyva. The drug is now indicated to treat follicular lymphoma, a subtype of non-Hodgkin's lymphoma, which accounts for a fifth of all cases in NHL. (PMLive)

close

Next Article in Data/Analytics